Literature DB >> 2757663

Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers.

L De Caro1, A Ghizzi, R Costa, A Longo, G P Ventresca, E Lodola.   

Abstract

The plasma pharmacokinetics of oral acetylcysteine(N-acetylcysteine, NAC) after the administration of single 600 mg and repeated 200 mg doses and the relative bioavailability of the two regimens were studied in 12 adult subjects. On two different occasions in a cross-over, balanced fashion the subjects were administered orally either a single dose of NAC 600 mg as effervescent tablets or 4 repeated doses of NAC as granules in sachets at the regimen of 200 mg t.i.d. Venous blood samples were obtained just before dosing and 20, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h after the administration of NAC 600 mg; with the 1st, the 2nd and the 4th doses of NAC 200 mg samples were taken just before dosing and after 20, 40 min, 1, 1.5, 2, 3, 4, 6 and 8 h, the last sampling after the 1st dose being the one before the 2nd dose. A detailed description of the assaying methods of NAC is given in the text. As indexes of bioavailability Cmax' tmax and AUC of NAC plasma concentrations were considered and MRT was taken as an estimate of its persistence in plasma. NAC was quickly absorbed without any significant difference in tmax among the doses. With the 600 mg dose Cmax' AUC and MRT were greater than with a single 200 mg dose; after summing up the values of these parameters for the 200 mg doses no significant differences were observed in comparison to the single 600 mg dose in Cmax and AUC, while MRT resulted significantly higher.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757663

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  19 in total

1.  N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis.

Authors:  January N Baumgardner; Kartik Shankar; Leah Hennings; Emanuele Albano; Thomas M Badger; Martin J J Ronis
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

2.  N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication.

Authors:  Luís Eduardo S Fontes; Ana Luiza C Martimbianco; Carolina Zanin; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2019-02-12

3.  Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Authors:  Marc R Mansour; Casie Reed; Amy R Eisenberg; Jen-Chieh Tseng; Jean-Claude Twizere; Sarah Daakour; Akinori Yoda; Scott J Rodig; Noa Tal; Chen Shochat; Alla Berezovskaya; Daniel J DeAngelo; Stephen E Sallan; David M Weinstock; Shai Izraeli; Andrew L Kung; Alex Kentsis; A Thomas Look
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

4.  The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage.

Authors:  L F Prescott; J W Donovan; D R Jarvie; A T Proudfoot
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of N-acetylcysteine.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

6.  Nrf2 activation protects the liver from ischemia/reperfusion injury in mice.

Authors:  Kazuhiro Kudoh; Hiroshi Uchinami; Masato Yoshioka; Ekihiro Seki; Yuzo Yamamoto
Journal:  Ann Surg       Date:  2014-07       Impact factor: 12.969

Review 7.  Environmental toxicity, redox signaling and lung inflammation: the role of glutathione.

Authors:  Saibal K Biswas; Irfan Rahman
Journal:  Mol Aspects Med       Date:  2008-08-08

8.  Oral taurine but not N-acetylcysteine ameliorates NEFA-induced impairment in insulin sensitivity and beta cell function in obese and overweight, non-diabetic men.

Authors:  C Xiao; A Giacca; G F Lewis
Journal:  Diabetologia       Date:  2007-11-17       Impact factor: 10.122

9.  N-Acetyl-L-cysteine and its derivatives activate a Cl- conductance in epithelial cells.

Authors:  M Köttgen; A E Busch; M J Hug; R Greger; K Kunzelmann
Journal:  Pflugers Arch       Date:  1996-02       Impact factor: 3.657

Review 10.  Role of N-acetylcysteine in the management of COPD.

Authors:  Anna M Sadowska; J Verbraecken; K Darquennes; W A De Backer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.